These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 24615631

  • 1. Ospemifene in the treatment of vulvovaginal atrophy.
    Barnes KN, Pearce EF, Yancey AM, Forinash AB.
    Ann Pharmacother; 2014 Jun; 48(6):752-7. PubMed ID: 24615631
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D, Palacios S, Nappi RE, Mueck AO.
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
    Wurz GT, Kao CJ, DeGregorio MW.
    Clin Interv Aging; 2014 Jun; 9():1939-50. PubMed ID: 25419123
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.
    Simon J, Portman D, Mabey RG, Ospemifene Study Group.
    Maturitas; 2014 Mar; 77(3):274-81. PubMed ID: 24411556
    [Abstract] [Full Text] [Related]

  • 8. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
    Portman DJ, Bachmann GA, Simon JA, Ospemifene Study Group.
    Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacologic evaluation of ospemifene.
    McCall JL, DeGregorio MW.
    Expert Opin Drug Metab Toxicol; 2010 Jun; 6(6):773-9. PubMed ID: 20429673
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
    Simon JA, Altomare C, Cort S, Jiang W, Pinkerton JV.
    J Womens Health (Larchmt); 2018 Jan; 27(1):14-23. PubMed ID: 29064335
    [Abstract] [Full Text] [Related]

  • 15. Treatment of dyspareunia secondary to vulvovaginal atrophy.
    Fantasia HC.
    Nurs Womens Health; 2014 Jan; 18(3):237-41. PubMed ID: 24939201
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis.
    Simon JA, Ferenczy A, Black D, Castonguay A, Royer C, Marouf R, Beauchemin C.
    Menopause; 2023 Aug 01; 30(8):855-866. PubMed ID: 37369079
    [Abstract] [Full Text] [Related]

  • 18. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.
    DeGregorio MW, Zerbe RL, Wurz GT.
    Steroids; 2014 Nov 01; 90():82-93. PubMed ID: 25087944
    [Abstract] [Full Text] [Related]

  • 19. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy.
    Nappi RE, Panay N, Bruyniks N, Castelo-Branco C, De Villiers TJ, Simon JA.
    Climacteric; 2015 Apr 01; 18(2):233-40. PubMed ID: 25335119
    [Abstract] [Full Text] [Related]

  • 20. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.
    Pinkerton JV, Kagan R.
    Expert Opin Pharmacother; 2015 Apr 01; 16(17):2703-14. PubMed ID: 26634778
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.